UL Solutions (ULS) Q3 2026 Earnings Call Transcript

UL Solutions reported Q3 2026 revenue of $823 million, up 5.1% year over year, with 7% organic growth and record adjusted EBITDA of $235 million, up 8.3%; adjusted EBITDA margin expanded 90 basis points to 28.6%. Adjusted diluted EPS rose 10.7% to $0.62, and management raised full-year organic revenue growth guidance to approximately 6.5%, while maintaining adjusted EBITDA margin guidance of approximately 27.0% amid higher transaction and integration costs of $37 million to $40 million. The company completed its approximately $686 million Eurofins E&E acquisition and sold its DQS stake for approximately $117 million; management cited expected integration costs above earlier estimates and weakness in Risk & Compliance Software margins, which fell to 18.9%.

Analysis

ULS’s upside case is less about a one-quarter margin record than whether testing demand converts into durable service revenue and better lab utilization. Certification work tied to data-center power and cooling can recur as product designs change, but the current growth signal is also exposed to customers’ R&D cycles; order growth outpacing recognized revenue is encouraging, not yet proof of a multiyear revenue stream. The key validation is continued testing growth followed by growth in recurring certification services.

Near term, reported margins may obscure operating progress: integration and transaction costs are elevated, while the divestiture has left Risk & Compliance Software with a smaller revenue base and weaker reported leverage. The 2026 margin outlook therefore should not be annualized from Q3. Over 6–18 months, E&E’s strategic value depends on cross-selling and lab utilization, with most stated synergies not expected until 2028; until then, execution and integration costs are the principal risks. Advisory weakness in U.S. renewables and commercial real estate is a separate drag, and could persist if those end markets remain soft.

Contrarian read: the software margin decline may look worse than the underlying retained portfolio, but management’s promised normalization needs evidence in subsequent quarters. The broader TIC opportunity is attractive, yet the market may be over-crediting AI demand if innovation cycles slow or lab capacity arrives ahead of customer work. Competitors such as SGS, Bureau Veritas and Intertek may also compete for incremental testing demand, limiting pricing upside.

Key Decisions for Investors

• Consider a staged long in ULS rather than chasing the quarter: add only if subsequent results sustain certification testing momentum and recurring-services growth without deterioration in full-year margin expectations. Thesis is falsified by a material slowdown in testing growth or a cut to organic growth guidance.
• Treat Q4 and early 2027 margin weakness as a watch item, not automatically a thesis break. Track integration costs against management’s stated range, Risk & Compliance Software’s margin recovery, and the 2027 completion of back-office integration; reassess if costs keep rising or software margins fail to normalize.
• Monitor E&E execution through disclosed revenue contribution, customer cross-selling and lab utilization. The payoff is back-end-loaded toward 2027–28, so do not underwrite near-term synergy as realized earnings; weaker utilization or integration disruption would impair the acquisition thesis.
• No immediate event-driven options trade is warranted from this call alone: the main catalysts are multi-quarter execution milestones, while advisory exposure and the timing of customer innovation cycles create meaningful uncertainty.